EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0AB6: Hyloris Pharmaceuticals SA

10 Nov 2025
LAST:

5.940

CHANGE:
 0.00		OPEN:
5.940		HIGH:
5.940		ASK:
0.000		VOLUME:
0
CHG(%):
0.00		PREV:
5.940		LOW:
5.940		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Nov 255.9405.9405.9405.9400
07 Nov 255.9405.9405.9405.9400
06 Nov 255.9405.9405.9405.9400
05 Nov 255.9405.9405.9405.9400
04 Nov 255.9405.9405.9405.9400
03 Nov 255.9405.9405.9405.9400
31 Oct 255.9405.9405.9405.9400
30 Oct 255.9405.9405.9405.9400
29 Oct 255.9405.9405.9405.940500
28 Oct 255.7005.7005.7005.700500

COMPANY PROFILE

Name:Hyloris Pharmaceuticals SA
About:Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. The company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream to treat vaginal infections caused by candida yeast and/or bacteria, including a biofilm; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; HY-091 for vulvar lichen sclerosis; HY-095 to treat equine gastric ulcer; Pantoprazole IV to treat gastric acidity, and ulcers and erosive esophagitis; Ondansetron for nausea and vomiting; and HY-094 to treat iron deficiency. It has collaboration agreement with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
Address:Boulevard Patience et Beaujonc N°3/1, Liège, Belgium, 4000
Website:https://hyloris.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-25.83 
Price to Sales:19.87 
Price to Book:5.63 
Profit Margin:-0.76 
Operating Margin:-1.06 
Return on Assets:-0.09 
Return on Equity:-0.20 
EPS Ratio:-0.45 
Revenue:8.46M 
Shares:28.0M 
Market Cap:166.32M 

TECHNICAL INDICATORS

MA5:5.940.0%
MA10:5.920.4%
MA20:5.861.3%
MA50:6.112.8%
MA100:6.255.2%
MA200:6.051.9%
STO14:100.00 
RSI14:80.00 
MTM14:0.24
ROC14:0.04 
ATR:0.02 
Week High:5.940.0%
Week Low:5.940.0%
Month High:6.184.0%
Month Low:5.701.9%
Volatility:9.36